

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Previously Presented) A method for treating chronic myelocytic leukemia (CML) in a patient, comprising administering to said patient a therapeutic composition comprising a pharmaceutically acceptable carrier and at least one naked anti-granulocyte antibody, wherein said anti-granulocyte antibody is an anti-NCA-90 antibody or an anti NCA-95 antibody.
2. (Original) The method of claim 1, wherein said anti-granulocyte antibody is an anti-NCA-90 antibody.
3. (Original) The method of claim 2, wherein said anti-NCA-90 antibody is MN-3.
4. (Original) The method of claim 1, wherein said anti-granulocyte antibody is an anti-NCA-95 antibody.
5. (Previously Presented) A method for treating chronic myelocytic leukemia (CML) in a patient, comprising administering to said patient a therapeutic composition comprising a pharmaceutically acceptable carrier and at least one naked anti-granulocyte antibody, wherein said anti-granulocyte antibody is selected from the group consisting of MN-2, MN-3, MN-15, NP-1 and NP-2.
6. (Cancelled)

7. (Previously Presented) The method of claim 1, wherein said anti-granulocyte antibody is selected from the group consisting of subhuman primate antibody, murine monoclonal antibody, chimeric antibody, humanized antibody and human antibody.

8. (Withdrawn) The method of claim 1, further comprising administering an immunoconjugate to said patient.

9. (Withdrawn) The method of claim 1, further comprising administering chemotherapy to said patient.

10.-17. (Cancelled)

18. (Previously Presented) The method of claim 1, wherein said therapeutic composition comprises two or more naked anti-granulocyte antibodies.

19. (Previously Presented) The method of claim 1, further comprising administering an anti-CD33 antibody.

20. (Original) The method of claim 19, wherein said anti-CD33 antibody is M-195.

21. (Previously Presented) The method of claim 1, further comprising administering an anti-CD15 antibody.

22.-24. (Cancelled)

25. (Previously Presented) The method of claim 5, wherein said anti-granulocyte antibody is selected from the group consisting of subhuman primate antibody, murine monoclonal antibody, chimeric antibody, humanized antibody and human antibody.

26. (Previously Presented) The method of claim 5, wherein said therapeutic composition comprises two or more naked anti-granulocyte antibodies.

27. (Previously Presented) The method of claim 5, further comprising administering an anti-CD33 antibody.
28. (Previously Presented) The method of claim 27, wherein said anti-CD33 antibody is M-195.
29. (Previously Presented) The method of claim 5, further comprising administering an anti-CD15 antibody.